News-20220803

----------Quote from the Company’s Website----------
Immunis, a private biotechnology company developing a novel treatment for age and disease-related immune decline, has closed a $10M Series A First Closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy, which is an age, disuse and disease-associated condition experienced by 100% of the population.
Taka Koda of Remiges Ventures has joined the company’s board of directors.
 
“The completion of this financing round reflects strong asset development, an outstanding team and a focused strategy,” said Dr. Hans S. Keirstead, Chairman of Immunis.
An inevitable consequence of aging is decline of immune system health. Immune system degeneration manifests many degenerative conditions within the body, including muscle atrophy. Mitigating the loss of muscle and improving muscle recovery are unmet medical needs. Immunis’ unique secretome treatment, IMMUNA (previously IMM01-STEM), addresses both medical needs using natural immunomodulators with potent cytoskeletal remodeling properties.
“This is a first-in-sector immunomodulatory secretome product, and Immunis is excited to be entering human clinical testing,” said Dr. Tom Lane, Chief Science Officer of Immunis. “The secretome is all natural, all human and represents a perfectly balanced set of immune modulators in naturally occurring, relevant physiological concentrations.”
 
# # # # #
 
About Immunis
 
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The IMMUNA product line leverages Immunis’ leading-edge capabilities in stem cell technology to deliver all natural, all human immune modulators in their natural, relative physiological concentrations.

-------unquote-------